Evidence map›Paper›PMID 36565182›Full record

Observational studyJournal of the American Heart Association2023

Interaction of Blood Pressure and Glycemic Status in Developing Cardiovascular Disease: Analysis of a Nationwide Real-World Database.

Yuta Suzuki, Hidehiro Kaneko, Yuichiro Yano, Akira Okada, Hidetaka Itoh, Satoshi Matsuoka, Isao Yokota, Takahiro Imaizumi, Katsuhito Fujiu, Nobuaki Michihata and 6 more

Open access · goldAbstract readObservational Study
In one paragraph

Observational study in Journal of the American Heart Association, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
2.0field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 8 institutions in 2 countries.

Yuta SuzukiThe Department of Cardiovascular Medicine The University of Tokyo Tokyo Japan.ORCID 0000-0002-9406-4691
Hidehiro KanekoThe Department of Cardiovascular Medicine The University of Tokyo Tokyo Japan.ORCID 0000-0003-2553-6170
Yuichiro YanoDepartment of Advanced Epidemiology, NCD Epidemiology Research Center Shiga University of Medical Science Shiga Japan.ORCID 0000-0002-2565-7290
Akira OkadaDepartment of Prevention of Diabetes and Lifestyle-Related Diseases, Graduate School of Medicine The University of Tokyo Tokyo Japan.ORCID 0000-0001-6480-3388
Hidetaka ItohThe Department of Cardiovascular Medicine The University of Tokyo Tokyo Japan.ORCID 0000-0001-6610-6201
Satoshi MatsuokaThe Department of Cardiovascular Medicine The University of Tokyo Tokyo Japan.ORCID 0000-0003-3642-2603
Isao YokotaDepartment of Biostatistics, Faculty of Medicine Hokkaido University Sapporo Japan.
Takahiro ImaizumiDepartment of Advanced Medicine Nagoya University Hospital Nagoya Japan.ORCID 0000-0003-3831-7241
Katsuhito FujiuThe Department of Cardiovascular Medicine The University of Tokyo Tokyo Japan.
Nobuaki MichihataThe Department of Health Services Research The University of Tokyo Tokyo Japan.ORCID 0000-0003-3091-114X
Taisuke JoThe Department of Health Services Research The University of Tokyo Tokyo Japan.ORCID 0000-0002-8503-022X
Norifumi TakedaThe Department of Cardiovascular Medicine The University of Tokyo Tokyo Japan.
Hiroyuki MoritaThe Department of Cardiovascular Medicine The University of Tokyo Tokyo Japan.
Koichi NodeDepartment of Cardiovascular Medicine Saga University Saga Japan.ORCID 0000-0002-2534-0939
Hideo YasunagaThe Department of Clinical Epidemiology and Health Economics, School of Public Health The University of Tokyo Tokyo Japan.ORCID 0000-0002-6017-469X
Issei KomuroThe Department of Cardiovascular Medicine The University of Tokyo Tokyo Japan.ORCID 0000-0002-0714-7182
The University of Tokyo · JPUniversity of Tokyo Health Sciences · JPHokkaido University of Science · JPNagoya University Hospital · JPSaga University · JPShiga University of Medical Science · JPSuzuki (Japan) · JPTakeda (Japan) · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background Hypertension and diabetes frequently coexist. However, little is known about the interaction between high blood pressure (BP) and hyperglycemia in the development of cardiovascular disease (CVD). Methods and Results We conducted an observational cohort study that included 3 336 363 patients (median age, 43 years old; men, 57.2%). People taking BP- or glucose-lowering medications or those with prior history of CVD were excluded. We defined stage 1 hypertension as having systolic BP of 130 to 139 mm Hg or diastolic BP of 80 to 89 mm Hg and stage 2 hypertension as having systolic BP of ≥140 mm Hg or diastolic BP of ≥90 mm Hg. We defined prediabetes as having fasting plasma glucose of 100 to 125 mg/dL and diabetes as having fasting plasma glucose of ≥126 mg/dL. Over a mean follow-up period of 1185 ± 942 days, 5665 myocardial infarction, 52 475 angina pectoris, 25 436 stroke, 54 508 heart failure, and 12 932 atrial fibrillation events occurred. The BP and fasting plasma glucose categories additively increased the risk of myocardial infarction, angina pectoris, stroke, heart failure, and atrial fibrillation. However, the relative risk of stage 1 and stage 2 hypertension developing into CVD was attenuated with deteriorating glycemic status. Similarly, the relative risk of prediabetes and diabetes developing into CVD was attenuated with increasing BP. For example, the relative risk reduction of stage 2 hypertension for heart failure was 53.5% in individuals with normal fasting plasma glucose, 46.4% in those with prediabetes, and 37.2% in those with diabetes. The robustness of our findings was confirmed using a multitude of sensitivity analyses. Conclusions Although hypertension and hyperglycemia additively increase the risk of developing CVD, the relative contribution of hypertension to the development of CVD decreased with deteriorating glycemic status and that of hyperglycemia was attenuated with increasing BP. Our results indicate a potential interaction between hypertension and hyperglycemia in the development of CVD.

Indexed as

Atrial FibrillationCardiovascular DiseasesHeart FailureHyperglycemiaHypertensionMyocardial InfarctionPrediabetic StateStrokeAdultAngina PectorisAntihypertensive AgentsBlood GlucoseBlood PressureCohort StudiesHumansMaleAntihypertensive AgentsBlood Glucosecardiovascular diseasediabetesepidemiologyhypertension

Identifiers

PMID36565182
PMCPMC9973580
OpenAlexW4313522166

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.